Monthly Archives: November 2019

Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Imprime PGG-induced IPD Changes Associated with Stable Disease, Progression-Free Survival and Overall Survival EAGAN, MN — November 8, 2019 — Biothera Pharmaceuticals, Inc. announced today immune pharmacodynamic data from its Phase 2 clinical study evaluating the therapeutic combination of Imprime PGG and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in chemo-refractory metastatic triple...

Read More


Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting EAGAN, MN — November 5, 2019 — Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in triple negative breast cancer and melanoma this week at the Society for Immunotherapy of Cancer annual meeting in the Gaylord...

Read More